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Abstract:  Bacillus  species  produce  extracellular,  surface-active  lipopeptides  such  as 
surfactin that have wide applications in industry and medicine. The steps involved in the 
synthesis of 3-hydroxyacyl-coenzyme A (CoA) substrates needed for surfactin biosynthesis 
are  not  understood.  Cell-free  extracts  of  Bacillus  subtilis  strain  OKB105  synthesized 
lipopeptide biosurfactants in presence of L-amino acids, myristic acid, coenzyme A, ATP, 
and H2O2, which suggested that 3-hydroxylation occurs prior to CoA ligation of the long 
chain  fatty  acids  (LCFAs).  We  hypothesized  that  YbdT,  a  cytochrome  P450  enzyme 
known to beta-hydroxylate LCFAs, functions to form 3-hydroxy fatty acids for lipopeptide 
biosynthesis. An in-frame mutation of ybdT was constructed and the resulting mutant strain 
(NHY1)  produced  predominantly  non-hydroxylated  lipopeptide  with  diminished 
biosurfactant and beta-hemolytic activities. Mass spectrometry showed that 95.6% of the 
fatty acids in the NHY1 biosurfactant were non-hydroxylated compared to only ~61% in 
the OKB105 biosurfactant. Cell-free extracts of the NHY1 synthesized surfactin containing 
3-hydroxymyristic acid from 3-hydroxymyristoyl-CoA at a specific activity similar to that 
of the wild type (17 ±  2 versus 17.4 ±  6 ng biosurfactant min
−1· ng· protein
−1, respectively). 
These results showed that the mutation did not affect any function needed to synthesize 
surfactin once the 3-hydroxyacyl-CoA substrate was formed and that YbdT functions to 
supply 3-hydroxy fatty acid for surfactin biosynthesis. The fact that YbdT is a peroxidase 
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could  explain  why  biosurfactant  production  is  rarely  observed  in  anaerobically  grown 
Bacillus species. Manipulation of LCFA specificity of YbdT could provide a new route to 
produce biosurfactants with activities tailored to specific functions. 
Keywords:  cytochrome  P450;  YbdT;  long  chain  fatty  acids;  beta  hydroxylation;  
Bacillus subtilis; surfactin 
 
1. Introduction 
Biosurfactants  are  surface-active  agents  produced  by  a  wide  variety  of  microorganisms  that 
partition at the water/air and water/oil interfaces [1]. By partitioning at these interfaces, biosurfactants 
can lower the surface and interfacial tensions between the two phases [1–4] and hence have a wide 
variety of applications in industry [1–4] and medicine [5].  
Biosurfactants  have  diverse  chemical  structures  including  glycolipids,  phospholipids,  and 
lipopeptides  [3].  One  of  the  most  studied  types  of  biosurfactants  is  lipopeptides  produced  by 
Bacillus spp. Most lipopeptide biosurfactants have been shown to have a structure similar to that of 
surfactin, the biosurfactant produced by Bacillus subtilis [6–9]. Surfactin as well as other lipopeptides 
produced  by  Bacillus  spp.  are  synthesized  non-ribosomally  through  the  action  of  non-ribosomal 
peptide synthetases (NRPS), which are large multifunctional enzymes with a modular organization of 
condensation,  adenylation,  and  thiolation  domains  [10–14].  The  activity  of  surfactinsynthetase 
(SrfABC) has been studied in detail over the past two decades [15–21]. Recently, it was shown that in 
the initiation reaction, the 3-hydroxy fatty acid substrate is transferred from coenzyme A (CoA) to 
SrfA,  where  3-hydroxyacyl-glutamate  is  formed  [22].  SrfD,  the  external  thioesterase  enzyme  in 
surfactin  biosynthesis,  was  shown  to  stimulate  the  formation  of  the  initiation  product  [22].  
Kraas et al. [23] showed that the condensation domain of the initiation module catalyzed the transfer 
of the CoA-activated 3-hydroxy long chain fatty acid (LCFA) to the peptidyl carrier protein-bound 
glutamate. They also showed that the activation of 3-hydroxy LCFA occurs via the activity of two acyl 
CoA  ligases  in  Bacillus subtilis  [23].  However,  the  reaction  involved  in  the  formation  of  the  
3-hydroxy-fatty acids needed for initiation of biosurfactant synthesis is not known.  
Previous work showed that changes in the amino acid and fatty acid composition of lipopeptides 
had a pronounced effect on lipopeptide activity [24–29]. Surfactin with a hydrophobic pentadecanoic 
fatty acid side chain was found to be the most active with regards to hemolytic activity [28]. Also, 
increasing the percentage of iso-even-numbered fatty acids compared to n-even-numbered fatty acids 
in  the  lipopeptide  biosurfactant  increased  the  activity  of  the  lipopeptide  as  determined  by  the  oil 
spreading  assay  [29]. The identification of  the enzyme responsible for 3-hydroxylation of LCFAs 
involved  in  biosurfactant  synthesis  could  potentially  provide  a  new  route  for  manipulation  of 
biosurfactant activity. By increasing the specificity of this enzyme towards branched versus straight 
chain and even- versus odd-numbered fatty acids, biosurfactants with a tailored mixture of 3-hydroxy 
fatty acyl moieties could be produced to suit the required task. Int. J. Mol. Sci. 2011, 12                       
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Cytochrome P450 enzymes are known to hydroxylate LCFAs in Bacillus sp. [30,31]. B. subtilis 
genome has genes for eight cytochrome P450 enzymes [30]. BioI (CYP107H1) catalyzes in-chain 
cleavage of fatty acids bound to ACP as part of pimelic acid formation during biotin biosynthesis, but 
can catalyze sub-terminal hydroxylation of LCFAs in vitro [32,33]. CYP102A2 and CYP102A3, the 
B. subtilis homologues of the flavocytochrome CYP102A1 from Bacillus megaterium, catalyze the 
sub-terminal hydroxylation of long chain unsaturated and branched chain fatty acids in the presence of 
heme, FAD, and FMN as cofactors [34]. PksS is involved in hydroxylation of polyketides [35], YjiB is 
proposed to be involved in the catabolism of hexuronate [36], CypA is proposed to be involved in the 
transport of branched-chain amino acids [37], and CypX (CYP134A1) is involved in the three-step, 
oxidative transformation of the diketopiperazinecyclo-L-leucyl-L-leucyl to pulcherriminic acid and has 
recently  been  recognized  as  a  cyclo-L-leucyl-L-leucyldipeptideoxidase  [38].  Only  one  cytochrome 
P450 enzyme, YbdT (CYP152A1), is known to hydroxylate LCFAs in the α/β position [39,40]. 
We mutated ybdT (CYP152A1) to test the role of YbdT in the formation of 3-hydroxy-LCFAs 
needed for lipopeptide biosurfactant synthesis. Manipulation of the YbdT active site to accommodate 
different  fatty  acids  is  discussed  with  reference  to  its  potential  for  enhancing  biosurfactant 
surface activity. 
2. Results 
2.1. In-Frame Mutation of ybdT in B. subtilis Strain OKB105 
The  initiation  of  surfactin  synthesis  involves  the  transfer  of  the  3-hydroxyacyl  moiety  from  
3-hydroxyacyl-CoA  to  SrfA  [22].  Whether  the  3-hydroxyacyl  moiety of  surfactin  is  derived  from  
3-hydroxyacyl-CoA generated in the beta-oxidation pathway or from the 3-hydroxylation of LCFAs is 
not known. We hypothesized that the LCFA 3-hydroxylating enzyme, YbdT, is responsible for the  
3-hydroxylation of the fatty acids used for surfactin synthesis. To test this hypothesis, we mutated the 
ybdT  via  transformation  of  competent  B.  subtilis  OKB105  cells  with  a  PCR  construct  carrying  a 
chloramphenicol-resistance  cassette  in-frame  with  the  ybdT  gene  sequence.  The  competence  of 
OKB105 was checked with a PCR product of rpoB gene that confers resistance to rifampicin. The 
percent transformation of OKB105 cells with rpoB gene was 2.05 ×  10
−4, comparable to a percent 
transformation  of  7.7  ×  10
−4  reported  previously  [41].  A  chloramphenicol-resistant  mutant  with 
delayed  hemolysis  of  blood  agar  (NHY1)  was  obtained  as  a  potential  ybdT
−  mutant  (Figure  1). 
Amplification and sequencing of the ybdT gene from NHY1 showed that the chloramphenicol-resistance 
cassette was inserted into the ybdT gene, confirming that NHY1 was a ybdT mutant. Int. J. Mol. Sci. 2011, 12                       
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Figure 1. β-hemolytic activity of the OKB105 cells compared to NHY1, the ybdT mutant. 
Blood  agar plate  was  streaked  with  a  single  colony  of  OKB105  (wild-type)  or NHY1 
(ybdT mutant) cells. β-Hemolysis occurred within 24 h in OKB105 cells with clearing of 
blood agar and the appearance of a green sheen. NHY1 cells showed delayed hemolysis, 
which occurred after 48 h of incubation, and was not as extensive as that observed with 
OKB105 cells. The picture was taken 24 h after streaking. 
 
2.2. YbdT Activity of OKB105 and NHY1 Cells 
YbdT  is  a  peroxygenase  that  requires  hydrogen  peroxide  for  catalysis  and  its  activity  can  be 
followed by the formation of 3-hydroxyl fatty acids from LCFA in the presence of H2O2 [39]. No 
myristic acid was detected by gas chromatography-mass spectroscopy (GC/MS) after OKB105 cell-free 
extracts  incubated  in  the  presence  of  myristic  acid  were  acid  precipitated  and  derivatized  with  
N,O-bis(trimethylsilyl)trifluoroacetamide  (BSTFA).  The  GC  chromatogram  showed  a  peak  that 
had the  same  retention  time  and  fragmentation  pattern  as  bis-trimethylsilyl  (TMS)-derivatized  
3-hydroxymyristic acid standard. The reaction mixture with the NHY1 cell-free extract contained only 
a peak for the TMS-derivative of myristic acid, and no peaks were detected upon extraction of the MS 
chromatogram at m/z of 233 (see Figure 2a for description of the mass spectrometry fragmentation of 
bis-TMS-derivatized 3-hydroxymyristic acid), indicating the absence of 3-hydroxy fatty acids. The 
absence of a hydroxylated fatty acid in NHY1 extracts confirmed that YbdT is a 3-hydroxylating 
LCFA peroxidase. 
Cell free extracts of OKB105 synthesized surfactin in the presence of the free fatty acid, CoA, and 
H2O2 with a specific activity of 31 ng biosurfactant· min
−1· ng· protein
−1, which is comparable to the rate 
when 3-hydroxymyristoyl-CoA was used (30 ng biosurfactant· min
−1· ng· protein
−1). 
2.3. Effect of the ybdT Gene Mutation on Surfactin Synthesis 
NHY1  cultures  had  reduced  oil-displacement  activity  (0.5  cm)  compared  to  OKB105  cultures  
(2  cm).  Upon  purification,  the  NHY1-biosurfactant  had  a  specific  activity  of  0.5  mm  of  oil 
displacement per µg  compared to 2.8 mm per µg  of OKB105 biosurfactant [29]. To rule out the 
possibility that the low biosurfactant activity of NHY1 was due to lack of expression of the srfABC 
operon, srf gene transcription in NHY1 was investigated with reverse transcriptase PCR. A band of the 
expected size (250 bp) was obtained with RNA extracted from NHY1 and OKB105 strains indicating 
that the surfactin synthesis gene was expressed in presence of the ybdT gene mutation.  Int. J. Mol. Sci. 2011, 12                       
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Table  1.  Surfactin  synthase  activity  in  OKB105  and  NHY1  cell-free  extracts  in  the 
presence of 3-hydroxymyristoyl-CoA
a. 
Cell-Free 
Extract 
Coenzyme A Release  
(nmol· min
−1· ng· protein
−1) 
3-Hydroxymyristoyl-CoA 
Consumption 
(nmol· min
−1· ng· protein
−1) 
Biosurfactant Production 
(ng· min
−1· ng· protein
−1) 
OKB105  0.018 ±  0.015 
b  0.002 ±  0.002 
b  17.4 ±  5.5 
b 
NHY1  0.018 ±  0.017  0.001 ±  0.001  17.0 ±  1.9 
Student’s  
t-test p-value 
0.98 
c  0.23 
c  0.51 
c 
a Each product was detected and quantified by high-pressure liquid chromatography. Standard curves were 
constructed  using  coenzyme  A,  enzymatically  synthesized  3-hydroxymyristoyl-CoA,  and  commercially 
available surfactin (Sigma
®); 
b Values are means ±  standard deviations of 9 measurements from 2 separate 
experiments for OKB105 extracts and 10 measurements from 2 separate experiments for NHY1 extracts for 
coenzyme A release and 3-hydroxymyristoyl CoA consumption assays. For biosurfactant production, the 
values are means ±  standard deviations of 3 measurements for each extract; 
c The p-value associated with 
Student’s t-test [42] was used to test the significant difference between enzyme activities of OKB105 and 
NHY1 extracts. 
 
As shown above, NHY1 did not hydroxylate LCFA. However, in the presence of 3-hydroxyacyl-CoA, 
NHY1 should be able to synthesize surfactin at a rate comparable to that of OKB105. To test this 
hypothesis, biosurfactant synthesis activity was determined in three ways (Table 1). There was no 
significant difference between cell-free extracts of NHY1 and OKB105 in the rate of biosurfactant 
formation as determined by the disappearance of 3-hydroxymyristoyl-CoA, the release of CoA, and 
the formation of surfactin. These data show that the ybdT mutation had no effect on surfactin synthase 
activity when 3-hydroxymyristoyl-CoA was supplied. 
2.4. Effect of ybdT Gene Mutation on Biosurfactant Structure 
Since  the  ybdT  gene  mutation  did  not  affect  the  enzyme  activity  of  surfactin  synthase,  we 
hypothesized that the ybdT mutation resulted in a biosurfactant with an altered structure, one with little 
to  no  3-hydroxyfatty  acids  and  thus  less  activity.  Biosurfactants  were  purified  from  NHY1  and 
OKB105 cultures. Amino acid analysis showed that the purified biosurfactants produced by NHY1 and 
OKB105 had the same amino acid composition: 1 Glu(n): 1 Asp(n): 1 Val: 4 Leu. 
The  non-polar  fatty  acid  tail  was  analyzed  by  GC/MS  after  methanolysis  and  acid  hydrolysis 
followed  by  derivatization  with  BSTFA  (Figure  2).  Acid  hydrolysis  and  methanolysis,  cyclic 
biosurfactants yield 3-hydroxy fatty acids and 3-hydroxy fatty acid methyl esters, respectively, which, 
after derivatization with BSTFA and MS fragmentation, will yield characteristic m/z ions of 233 and 
175, respectively (Figure 2A). In contrast, acid hydrolysis and methanolysis of acyclic biosurfactants 
generate fatty acids or fatty acid methyl esters, respectively (Figure 2B). Only the former is derivatized 
with  BSTFA  and  MS  fragmentation  yields  characteristic  m/z  ions  of  117  and  74,  respectively 
(Figure 2B) (see the American Oil Chemist’s Society’s lipid library archive [43–45], and Reference [46] 
for published procedures and spectra). Int. J. Mol. Sci. 2011, 12                       
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Figure 2. Summary of the outcome of acid hydrolysis and methanolysis of (A) a cyclic 
lipopeptide biosurfactant, and (B) an acyclic (linear) lipopeptide biosurfactant. Each type 
of biosurfactant was either acid hydrolyzed or methanolyzed (as described in text) with the 
release of a free fatty acid, or a fatty acid methyl ester (FAME), respectively. The fatty acid 
and FAME were then derivatized, separated by gas chromatography, and identified by 
mass spectrometry. Dotted line refers to the fragmentation pattern of the mass ion used to 
extract the MS chromatogram as explained in text. 
 
Following  methanolysis,  3-hydroxylated  fatty  acids  methyl  esters  (FAME)  of  chain  lengths  of 
C13, C14,  and  C15  comprised  33.4%  of  total  FAME  detected  in  the  OKB105  biosurfactant.  
Non-hydroxylated FAME with a chain length of C13–C18 accounted for 66.6% of the total FAME in 
the OBK105 biosurfactant. The NHY1 biosurfactant, on the other hand, had only 6.7% of the total Int. J. Mol. Sci. 2011, 12                       
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FAME  as  3-hydroxylated  FAME,  which  had  chain  lengths  of  C13–C15,  while  the  overwhelming 
majority of FAME (93.3%) were non-hydroxylated and had chain lengths of C12, C13, C14, C16, and 
C18 (Table 2). 
Analysis of fatty acid composition of the OKB105 and NHY1 biosurfactants after acid hydrolysis 
and  BSTFA  derivatization  confirmed  that  the  NHY1  biosurfactant  had  a  very  low  percentage  of  
3-hydroxylated  fatty  acids  (Table  2).  3-Hydroxylated  fatty  acids  with  chain  lengths  of  C13–C15 
comprised 44.6% of total fatty acids of the OKB105 biosurfactant. Non-hydroxylated fatty acids with 
chain lengths of C14–C18 accounted for 55.4% of the total fatty acids in the OKB105 biosurfactant. 
NHY1 biosurfactant had 3-hydroxylated fatty acids with chain lengths of C14 that comprised only 
2.2% of the total fatty acids, while the majority of fatty acids (97.8%) were non-hydroxylated and had 
chain lengths of C12, and C14–C18 (Table 2). 
The  molecular  weights  of  OKB105  and  NHY1  biosurfactants  were  determined  by  liquid 
chromatography-mass spectrometry (LC/MS) [7,47–49] (Table 3). The biosurfactants were dissolved 
under conditions in which the lactone ring should remain intact (room temperature in 10 mM NH4OH). 
Under these conditions, a difference in molecular weight of +2 units corresponds to the absence of the 
3-hydroxyl group. OKB105 biosurfactant had peaks corresponding to 3-hydroxy fatty acids ranging 
from 11 to 16 carbons (Table 3). Three peaks of lower intensities were detected that corresponded to 
non-hydroxylated  fatty  acids  with  12  and  13  carbons.  The  presence  of  non-hydroxylated  acyclic 
structures in the biosurfactant produced by Bacillus sp. has been reported before [50]. The NHY1 
biosurfactant had peaks corresponding to molecules with non-hydroxylated fatty acids with 11, 12, 13, 
14, and 16 carbons (Table 3). Three peaks with lower intensities corresponding to 3-hydroxy fatty 
acids with 12, 13, and 14 carbons were detected. 
3. Discussion 
Steller et al. [22] showed that 3-hydroxymyristoyl-CoA is transferred from CoA to SrfA to initiate 
lipopeptide  biosynthesis.  The  origin  of  3-hydroxyacyl-CoA  needed  for  lipopeptide  biosurfactant 
synthesis  was  not  known.  OKB105  cell-free  extracts  synthesized  lipopeptide  biosurfactants  in  the 
presence  of  myristic  acid,  CoA,  and  H2O2,  which  suggested  that  3-hydroxylation  preceded  CoA 
ligation of the LCFA used for biosurfactant synthesis. Our data provide convincing evidence that 
YbdT functions to 3-hydroxylate LCFA for lipopeptide biosurfactant synthesis. NHY1 had diminished 
hemolytic and biosurfactant activity. Over 90% of the fatty acids of the NHY1 biosurfactant were  
non-hydroxylated  compared  to  60%  non-hydroxylated  fatty  acids  in  the  OKB105  biosurfactant 
(Table 3). NHY1 made the wild-type biosurfactant only in the presence of 3-hydroxymyristoyl-CoA, 
while  OKB105  made  biosurfactant  from  both  3-hydroxymyristoyl-CoA  and  myristic  acid,  H2O2,  
and CoA. 
 Int. J. Mol. Sci. 2011, 12                       
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Table 2. Fatty acid composition of OKB105 and NHY1 biosurfactants. 
Fatty Acid 
(FA) Chain 
Length 
OKB105 Biosurfactant Fatty Acid Composition  NHY1 Biosurfactant Fatty Acid Composition 
Non-Hydroxylated FA  3-Hydroxylated FA  Non-Hydroxylated FA  3-Hydroxylated FA 
Methanolysis 
a  Acid Hydrolysis
 a  Methanolysis  Acid Hydrolysis  Methanolysis  Acid Hydrolysis  Methanolysis  Acid Hydrolysis 
12  ND
 c  ND  ND  ND  8.61 (1)
 b  21.2 (1)  ND  ND 
13  11.6 (1)  ND  10.26 (3)  1.87 (2)  13.06 (1)  ND  1.99 (1)  ND 
14  18.23 (2)  6.18 (2)  5.15 (2)  0.63 (1)  1.92 (1)  12.6 (2)  3.57 (1)  2.18 (2) 
15  61 (1)  19.9 (2)  31.3 (3)  8.9 (2)  ND  5.46 (2)  7.28 (2)  ND 
16  3.42 (1)  32.6 (2)  ND  ND  25.3 (3)  36.2 (2)  ND  ND 
17  ND  10.1 (1)  ND  ND  ND  4.19 (1)  ND  ND 
18  26.2 (2)  25.3 (2)  ND  ND  60.1 (3)  31 (2)  ND  ND 
Total  66.6 (3)  55.4 (2)  33.4 (3)  44.6 (2)  93.3 (3)  97.8 (2)  6.72 (3)  2.18 (2) 
Avg.  60.97  39  95.6  4.4 
a Methanolysis and acid hydrolysis refer to the method used for hydrolysis of the biosurfactant fatty acid; 
b Numbers are the percentage of the fatty acid calculated from the 
peak areas of gas chromatogram. Numbers in parenthesis are the number of times the isomer was detected. Three methanolysis and two acid hydrolysis preparations were 
analyzed; 
c ND: not detected. 
Table 3. Molecular weights of OKB105 and NHY1 biosurfactants determined by electrospray ionization mass spectrometry. 
Deduced FA Chain 
Length 
OKB105 Biosurfactant 
a  NHY1 Biosurfactant 
a 
M + H
+ b  M + Na
+ b  M + 2Na
+ − H
+ b  M + H
+ b  M + Na
+ b  M + 2Na
+ − H
+ b 
11      1024    1004   
12    1018  1040    1016, 1018   
13  1008  1032      1030, 1032   
14  1022  1044      1044, 1046   
15  1036  1058         
16  1050  1072    1052     
a Biosurfactants from the OKB105 and NHY1 cultures were purified and subjected to electrospray ionization mass spectrometry in the negative mode; 
b Numbers are the 
molecular mass of the detected ionized species as indicated in the column header. Numbers in bold refer to molecular weights that are +2 mass units greater than the 
corresponding  3-hydroxy  fatty  acid  and  indicate  a  non-hydroxylated  acyclic  structure.  Peaks  with  mass  units  1018,  1040,  and  1032  in  the  OKB105  biosurfactant 
corresponding to the non-hydroxylated acyclic isomers had intensities ranging from 800 to 1150 counts compared to intensities ranging from 850 to 2400 counts for the 
other peaks. Also, peaks with mass units 1016, 1030, and 1044 in the NHY1 biosurfactant corresponding to the hydroxylated cyclic isomers had intensities ranging from 
850 to 1200 counts compared to intensities ranging from 1000 to 5900 counts for the other peaks. Int. J. Mol. Sci. 2011, 12                       
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Our  PCR  analyses  indicated  that  the  only  difference  between  the  OKB105  and  NHY1  is  the 
ybdT gene interruption. However, we were unable to introduce the wild-type gene into NHY1 to prove 
that disruption of this gene alone caused the NHY1 phenotype. Despite this, our studies show that 
NHY1  can  synthesize active biosurfactant if  3-hydroxylacyl-CoA substrates are added to cell-free 
extract (Table 1). Thus, it seems reasonable to conclude that YbdT is required to hydroxylate LCFA 
for use in biosurfactant biosynthesis. 
The greatly diminished amount of 3-hydroxyl fatty acids in NHY1 biosurfactant would explain its 
lower  surface  activity  compared  to  the  OKB105  biosurfactant.  Without  a  hydroxyl  group  in  the  
3-position, the lactonization or cyclization of the biosurfactant would not be possible. Saponification of 
surfactin to form a linear structure changed its tertiary structure due to the partial topological disorder 
of the hydrophilic carboxyl group and the hydrophobic fatty acyl group [51]. The oil displacement 
activity  of  linear  surfactin  was  only  one-third  of  the  cyclic  form.  We  found  that  the  NHY1 
biosurfactant activity was about one-fourth of the OKB105 biosurfactant.  
Previously, we found that many B. subtilis strains that produced biosurfactants aerobically, did not 
show any surface activity when grown under strict anaerobic conditions [29]. Possible explanations for 
this observation could be that the ybdT gene is not expressed or YbdT is not functional under anaerobic 
conditions. YbdT is a cytochrome P450 enzyme that requires H2O2 for its function. H2O2 would be 
made only when oxygen contamination occurred. Thus, YbdT, if present, would not be active under 
anaerobic growth conditions. If surfactin synthase was made anaerobically, it would make lipopeptides 
with non-hydroxylated fatty acids, which would form a linear lipopeptide with much lower surface 
activity than the cyclic counterpart [51]. The activity of any linear biosurfactants may have been too 
low  to  be  detected  when  biosurfactant  activity  of  culture  fluids  are  screened  by  drop  collapse  or  
oil-spreading assays. 
Previous  work  showed  that  surface  activity  of  lipoheptapeptides  with  structures  analogous  to 
surfactin  increased  when  the  ratio  of  iso-  to  normal-even-numbered  long  chain  fatty  acids  in  the  
non-polar tail increased [29]. The identification of the enzyme responsible for the 3-hydroxylation of 
LCFA may provide a new route to optimization of biosurfactant surface activity by manipulation of the 
substrate specificity of the 3-hydroxylating enzyme. The substrate-binding pocket of YbdT has been 
identified [40]. Two types of interactions are involved: hydrophobic interactions with the fatty acid 
side chain and ten residues of YbdT and electrostatic interactions with the carboxyl group of the fatty 
acid with Arg242 [40]. Site-directed mutagenesis of the ten amino acids involved in the hydrophobic 
interactions  with  the  alkyl  side  chain  could  yield  enzymes  with  altered  specificity  towards  
branched-chain and longer chain fatty acid tails. It may be possible then to tailor the activity of the 
biosurfactant to different kinds of oils or for other uses by making biosurfactants with different fatty 
acid compositions.  
4. Experimental Section  
4.1. Strains, Plasmids and Growth Conditions 
B. subtilis strain OKB105 was obtained from the Bacillus Genetic Stock Center (BGSCID:1A698). 
Rifampicin-resistant  Bacillus  mojavenesis  strain  JF-2  was  obtained  by  heavily  streaking  the Int. J. Mol. Sci. 2011, 12                       
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rifampicin-sensitive strain on LB plates with 10 µ g/mL rifampicin and incubation at 37 ° C for several 
days until growth occurred. Rifampicin resistance is conferred by a spontaneous mutation in cluster I 
of  rpoB  gene  resulting  in  amino  acid  replacements:  Q469R,  H482R,  H482Y,  or  S487L  [52,53]. 
Escherichia coli harboring the chloramphenicol acetyl transferase (cat)-encoding plasmid PDG1662 
was obtained from the Bacillus Genetic Stock Center (BGSCID:ECE113).  
B. subtilis strain OKB105 was grown in minimal medium E [29] at 37 ° C for 40–44 h without 
shaking. Cells were then harvested and used for RNA extraction or cell-free extract preparation as 
described previously [54]. The cell-free supernatant was used for biosurfactant purification [29]. Blood 
agar plates [55] were used for secondary screening of mutants for biosurfactant production because 
surfactin-producing strains are known to be β-hemolytic [6]. 
4.2. PCR Construct Preparation 
An overlap PCR approach [56–58] was used to create a PCR construct of ybdT gene with a cat gene 
insertion (Figure 3).  
 
Figure 3. The overlap PCR protocol used to generate a ybdT mutation in OKB105. Primers 
P1 and P2 amplified the 5’ region of ybdT gene in OKB105. Primers P5 and P6 amplified 
the 3’ region of ybdT gene. Primers P3 and P4 amplified the chloramphenicol resistance 
cassette from PDG1662. Primers P2 P3, P4 and P5 were designed with 18 bp overlap as 
shown in Table 4. PCR1, PCR2, and PCR3 are the primary PCR products with overlapping 
region as follows: the 3’end of PCR1 contains sequence for the upstream portion of the cat 
and the 5’ end of PCR3 has sequence for amino acids 149–151 encoded by ybdT (blue). 
The 5’end of PCR2 contains sequence for amino acids 214–226 encoded by cat and 3’end 
of PCR3 has sequence for amino acids 365–367 encoded by ybdT (red). The primary PCR 
products were then joined in a long PCR reaction to synthesize the PCR construct used for 
transforming competent OKB105 cells. 
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Table 4. Primers used in this study. 
Primer  Sequence (5’-3’) 
P1F 
a  ATGAATGAGCAGATTCCACATGACAAAAGT 
P2R 
a  TGCCTCCTAACCTGCCCAATAGCACGCTACCCG 
P3F 
a  TGGGCAGGTTAGGAGGCAATGAACTTTAAT 
P4R 
a  AATGCCTTCTAAAAGCCAGTCATTAGG 
P5F 
a  TGGCTTTTAGAAGGCATTACAATTGAAGTCAT 
P6R 
a  ACTTTTTCGTCTGATTCCGCTCATTACGAA 
Srf1F 
b  GCGGTAGAAAAACTGCTTGC 
Srf1R 
b  ACAGGTTCGTCTGCTTTGCT 
rpoBF 
c  TCAACTAGTTCAGTATGGACG 
rpoBR 
c  ACCTGGTTCAGGAACATTGTC 
a Primers P1–P6 were used for the PCR construct. P1 and P2 amplify the 5’ region of ybdT gene, P5 and P6 
amplify the 3’ region of the ybdT gene, and P3 and P4 amplify the chloramphenicol resistance cassette. 
Underlined regions and italicized regions in P2 and P3 and in P4 and P5 are complementary and are used to 
create the 18 bp overlap in each case; 
b Primers Srf1F and Srf1R amplify a 250 bp region of surfactin 
synthesis (srf) operon; 
c Primers rpoBF and rpoBR amplify a 3.3 Kb region of rpoB gene. 
 
DNA was extracted from B. subtilis OKB105 cells grown in medium E by using QIAamp DNA 
Mini Kit (Qiagen
®, Valencia, CA, USA). E. coli harboring PDG1662 plasmid was grown according to 
manufacturer’s  instructions  and  plasmid  DNA  was  extracted  using  Plasmid  Mini  Kit  (Qiagen
®, 
Valencia, CA, USA). Six primers were utilized to create three PCR products (Table 4), which were 
then joined in the overlap PCR reaction (Figure 2).  
All PCR reactions were conducted in 50 µ L volume. The reaction contained 2 µ L of OKB105 or 
PDG1662  DNA, 1 ×   PCR buffer with magnesium sulfate (Roche
®, Boulder, CO, USA), 0.2  mM 
dNTPs mixture, 0.5 U of the Expand Long Template PCR System Taq polymerase (Roche
®, Boulder, 
CO, USA), and 10 µM  each of the forward and the reverse primers. The PCR reaction was carried out 
according to the following protocol: initial denaturation at 95 ° C for 5 min, followed by 30 cycles of 
denaturation at 95 ° C for 1 min, annealing at 65 ° C for 1 min, and elongation at 72 ° C for 1 min. A 
final  elongation  step  at  72 ° C  for  5  min  was  included.  For  cat  PCR,  the  number  of  cycles  was 
increased to 35 and the annealing temperature was 50 ° C. PCR products of the 5’ ybdT, 3’ ybdT, and 
cat were purified using MinElute PCR purification kit (Qiagen
®, Valencia, CA, USA). The purified 
products were quantified spectrophotometrically. To create the PCR construct by the overlap PCR 
protocol,  each  reaction  contained  0.3  µg   of  each  purified  PCR  product,  1  ×  PCR  buffer  with 
magnesium sulfate (Roche
®, Boulder, CO, USA), 0.2 mM dNTPs mixture, and 0.5 U of the Expand 
Long Template PCR System Taq polymerase (Roche
®, Boulder, CO, USA). The PCR protocol used 
was an initial denaturation at 95 ° C for 5 min followed by 15 cycles of denaturation at 95 ° C for 30 s, 
annealing at 55 ° C for 30 s, and elongation at 72 ° C for 30 s. Following the first 15 cycles, 10 µM  each 
of primers P1 and P6 were added to each reaction tube followed by 25 cycles of 95 ° C for 30 s, 60 ° C 
for 30 s, and 72 ° C for 5 min, plus an increment of 30 s for each cycle. A final elongation step at 72 ° C 
for 10 min was included. The PCR construct (expected size 1260 bp) was purified using QIAquick gel 
extraction kit (Qiagen
®, Valencia, CA, USA). Int. J. Mol. Sci. 2011, 12                       
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4.3. Transformation 
Competent cells of strain OKB105 were prepared according to the procedure of Cutting and Vander 
Horn [59]. To check for competence, OKB105 cells were transformed with the rpoB gene of the 
rifampicin-resistant Bacillus mojavenesis strain JF-2 [52,53]. DNA of Bacillus mojavenesis strain JF-2 
rif 
r was extracted using QIAamp DNA Mini Kit (Qiagen
®, Valencia, CA, USA), and the rpoB gene 
was amplified using primers rpoBF and rpoBR (Table 4). The reaction contained 2 µ L of the extracted 
DNA, 1 ×  PCR buffer with magnesium sulfate (Roche
®, Boulder, CO, USA), 0.2 mM dNTPs mixture, 
0.5 U of the Expand Long Template PCR System Taq polymerase (Roche
®, Boulder, CO, USA), and 
10 µM  each of the forward and the reverse primers. PCR protocol was an initial denaturation at 95 ° C 
for 5 min followed by 35 cycles of denaturation at 95 ° C for 1 min, annealing at 50 ° C for 1 min, and 
elongation at 72 ° C for 3 min. A final elongation step at 72 ° C for 5 minutes was included. The PCR 
product (~3.3 Kb) was purified using MinElute PCR purification kit (Qiagen
®, Valencia, CA, USA) 
and used to transform OKB105 competent cells [59]. OKB105 competent cells were then transformed 
with the ybdT-cat PCR construct. 
  To induce the chloramphenicol-resistance genes, the transformed cells were added to antibiotic-free 
LB plates in an overlay of LB soft agar with 0.1 mL of 50 µg/mL chloramphenicol followed by a 2 h 
incubation at 37 ° C. A second overlay of LB soft agar with 0.1 mL of 2 mg/mL chloramphenicol was 
then added and the plates were incubated at 37 ° C for 1–2 days until colonies were visible [59]. 
Colonies  were  streaked  onto  blood  agar  plates  to  identify  transformants  that  were  non-hemolytic, 
indicating  that  they  produced  little  or  no  biosurfactant.  The  ybdT  gene  was  amplified  from 
chloramphenicol-resistant,  non-hemolytic  mutants  using  primers  P1  and  P6  (Table  4).  The  PCR 
product was purified and sent for sequencing at the Oklahoma Medical Research Foundation. One 
chloramphenicol-resistant, non-hemolytic mutant (NHY1) with the chloramphenicol cassette inserted 
into the ybdT gene was characterized further.  
4.4. Expression of srf (Surfactin Synthetase) Gene 
Cell pellets of OKB105 (wild type) and NHY1 were first stabilized with RNAprotect Bacteria 
reagent (Qiagen
®, Valencia, CA, USA) before RNA purification with RNeasy Protect Bacteria Mini 
kit (Qiagen
®, Valencia, CA, USA). DNA was digested during RNA extraction with RNase-Free DNase 
set (Qiagen
®, Valencia, CA, USA). RNA from both OKB105 and NHY1 were reverse-transcribed to 
cDNA  using  gene-specific  primers  P6  for  ybdT  and  SrfR  for  srf1  using  SuperScript  II  Reverse 
Transcriptase  kit  (Invitrogen
®,  Carlsbad,  CA,  USA)  according  to  manufacturer’s  instructions.  The 
cDNA from OKB105 and NHY1 was then used in PCR reactions to amplify ybdT and srf genes. As a 
control,  purified  RNA  was  used  as  the  template  for  the  PCR  reaction  in  the  absence  of  reverse 
transcriptase to verify that the preparation did not contain DNA. 
4.5. Assay of YbdT Activity 
Cell-free extracts were prepared as described previously [54] with the exception that the ammonium 
sulfate fractionation step was omitted. The peroxygenase activity of YbdT was measured in cell-free 
extracts  of  OKB105  (wild  type  strain)  as  described  before  [39].  The  reaction  mixture  (0.2  mL) Int. J. Mol. Sci. 2011, 12                       
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contained 0.1 M potassium phosphate buffer (pH 5.9), 1.32 mM H2O2, and 60 µM  myristic acid. The 
reaction was started by the addition of the cell free extract followed by incubation at 37 ° C for 10 min. 
The reaction was stopped by the addition of 50 µ L of 12 N HCl. The reaction mixture was extracted 
with 250 µ L of ethyl acetate: hexane (1:1 v/v). The organic layer was evaporated and the residue was 
derivatized with N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) (Pierce, Rockford, IL, USA) and 
analyzed  by  GC/MS  (Agilent  Technologies  6890N  Network  GC  systems/5973  Network  Mass 
Selective Detector, Willmington, DE, USA) [29]. One microliter was used for injection. The oven 
temperature was set at 60 ° C for 5 min and then increased to 250 ° C over a 15 min interval. The 
column was a capillary column 0.25 mm ×  30 m ×  0.25 µ m. The carrier gas was helium and the flow 
rate was 1.2 mL/min. The mass spectrometer was operated at 400 Hz. Peak areas obtained on the 
GC chromatogram were used to calculate the percentage of the 3-hydroxy fatty acids compared to the 
area of all detected fatty acids. The mass spectrum at m/z ratio of 233, which is characteristic of  
bis-trimethylsilyl  (TMS)-derivatized,  3-hydroxy  fatty  acids  (Figure  2),  was  extracted.  Bis-TMS 
derivatized 3-hydroxymyristic acid (Larodan Fine Chemicals
®, Malamö , Sweden) was used as the 
standard. Protein concentrations were determined by the method of Bradford [60] using bovine serum 
albumin as a standard. 
4.6. Biosurfactant Synthesis in Cell-Free Extracts from L-Amino Acids and 3-Hydroxymyristoyl-CoA 
Cell-free  extracts  of  NHY1  and  OKB105  were  prepared  and  subjected  to  ammonium  sulfate 
fractionation as described previously [54]. Protein that precipitated between 30–70% saturation with 
ammonium sulfate was desalted and eluted in 3.5 mL volume using Amersham
® (GE Healthcare, 
Piscataway, NJ, USA) desalting columns PD10 according to the manufacturer’s instructions. Cell-free 
extracts were tested for the ability to synthesize surfactin [54]. 
The synthesis of surfactin from the  L-amino acids and 3-hydroxymyristoyl-CoA in presence of  
Mg-ATP was performed in a 0.5 mL reaction mixture that contained: 10 mM ATP, 10 mM MgCl2, 
13 mM dithioeryhthritol (DTE), 5 mM each of L-aspartate, L-glutamate, and L-valine, 0.5 mM L-leucine, 
80 mM TrisHCl (pH 7.8), 0.1 mM of 3-hydroxymyristoyl-CoA, 1.3 mM potassium phosphate, and 
1 mM ethylenediamine tetra-acetic acid (EDTA). The reaction was started by the addition of cell-free 
extract to give 20, 50, 100, 200, and 200 µ g/mL, incubated at 37 ° C for 60 min, and stopped by 
placing the mixture on ice [54]. The reaction was monitored by following the disappearance of the  
3-hydroxymyristoyl-CoA, the release of CoA, and the production of the biosurfactant by high-pressure 
liquid chromatography (HPLC).  
The concentration of 3-hydroxymyristoyl CoA was determined by using a HPLC equipped with an 
Alltech Prevail™ C18, 5 µ m, 4.6 ×  150 mm column (Grace Discovery Sciences, Deerfield, IL, USA), 
a mobile phase of 75% methanol and 25% 25 mM KH2PO4 (pH 5.3) and UV detection at 259 nm. The 
amount of 3-hydroxymyristoyl-CoA in the reaction mixture over time was determined by comparison 
of peak area to a standard curve prepared with known concentrations of 3-hydroxymyristoyl-CoA. 
Results  were  corrected  for  abiotic  loss  of  3-hydroxymyristoyl-CoA  determined  from  controls  that 
lacked cell-free extract. 
The concentration of CoA in the reaction mixture over time was determined by HPLC with an 
Alltech Prevail™ C18, 5 µ m, 4.6 ×  150 mm column (Grace Discovery Sciences, Deerfield, IL, USA), Int. J. Mol. Sci. 2011, 12                       
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a mobile phase of 5% acetonitrile in 25 mM KH2PO4 (pH 5.3), and UV detection at 259 nm. Peak 
areas were compared to a standard curve prepared with known amounts of CoA and corrected for CoA 
production in controls that lacked cell-free extract. 
Biosurfactants in the reaction mixture were concentrated by precipitation with 40% ammonium 
sulfate overnight at room temperature followed by centrifugation and re-dissolving the pellet in a 
minimal  volume  of  water.  The  purified  biosurfactants  were  quantified  by  using  HPLC  with  an 
Alltech Prevail™ C18, 5 µm, 4.6 ×  150 mm column (Grace Discovery Sciences, Deerfield, IL, USA), 
a mobile phase of 70% acetonitrile, and 30% 25 mM KH2PO4 (pH 5.3), and UV detection at 210 nm. 
A  standard  curve  of  the  commercially  available  surfactin  (Sigma)  was  used  to  calculate  the 
concentration  of  the  biosurfactant  in  the  reaction  mixture  compared  to  controls  that  lacked  
cell-free extracts. 
4.7. Enzymatic Preparation of 3-Hydroxymyristoyl-CoA 
Instead of the chemical synthesis used by Ullrich et al. [54] to synthesize 3-hydroxymyristoyl-CoA, 
we  synthesized  3-hydroxymyristoyl-CoA  enzymatically  with  an  acyl-CoA  synthase  enzyme  from 
Pseudomonas  sp.  available  from  Sigma
®.  This  enzyme  has  been  used  before  to  synthesize  CoA 
derivatives of dicarboxylic acids [61]. First, we determined that 3-hydroxymyristic acid (Larodan Fine 
Chemicals
®, Malamö , Sweden) could be used as a substrate by the acyl CoA synthase. The reaction 
mixture  contained:  50  mM  TrisHCl  (pH  8),  5  mM  MgCl2,  390  µM   NADH,  5  mM  ATP, 
0.38 mM CoA,  8  U  of  myokinase,  7.4  U  of  pyruvatekinase,  9.3  U  of  lactate  dehydrogenase, 
1.06 mM phosphoenolpyruvate, and 0.025 mg of 3-hydroxymyristic acid in a final volume of 0.6 mL. 
The  reaction  was started  by the  addition of  0.04 U of acyl-CoA synthase and incubated  at room 
temperature for 5 min. The reaction was followed by measuring the loss of absorbance at 340 nm due 
to the oxidation of NADH coupled the production of AMP [62].  
To synthesize 3-hydroxymyristoyl-CoA, 15 mg (60 µmol) of the free acid, 0.12 mmol of CoA, 
0.54 mmol of ATP, and 1.92 U of acyl-CoA synthase were combined in a final volume of 50 mL of 
50 mM Tris HCl and 5 mM MgCl2. The reaction was incubated at room temperature for 5 hours with 
low-speed stirring, after which an additional 0.12 mmol of CoA and 0.54 mmol of ATP were added 
and the reaction incubated at room temperature overnight [63].  
4.8. Purification and Quantification of the 3-Hydroxymyristoyl CoA 
Prevail™  10 g-Solid-Phase-Extraction  C18  columns  (Grace  Discovery  Sciences,  Deerfield,  IL, 
USA) were used for the 3-hydroxymyristoyl-CoA purification. Columns were activated with methanol, 
followed by deionized water, and then 100 mM MOPS-NaOH buffer. The 50 mL reaction was loaded 
on the activated columns and the unreacted CoA was eluted using 50 mL of MOPS-NaOH, followed 
by  50  mL  of  50%  methanol  until  the  absorbance  at  260  nm  of  the  eluant  approached  zero.  The  
3-hydroxymyristoyl-CoA was then eluted from the column using 100% methanol until the absorbance 
at 260 nm of the eluant approached zero. The 100% methanol fractions were combined and evaporated 
under N2 overnight. The residue was dissolved in 0.1 mM dithiothreitol (DTT) and stored at −70 ° C 
until used [63]. The purity of the product was checked using HPLC with a Discovery RP-Amide C16 
column (Supelco) (25 cm ×  4.6 mm, 5 µ m). The flow rate was 1 mL min
−1 using 20 mM ammonium Int. J. Mol. Sci. 2011, 12                       
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formate  pH  5  with  an  initial  concentration  of  5%  acetonitrile.  After  5  min,  the  acetonitrile 
concentration was increased over a 10 min period to 15%. Peaks were detected at 254 nm and further 
monitored using a diode array detector to scan from 210 to 400 nm. Injection volume was 20 µ L. To 
quantify  the  amount  of  3-hydroxymyristoyl-CoA  present,  an  aliquot  was  hydrolyzed  in  base  by 
adjusting the pH to 10–11 with NaOH followed by incubation at room temperature for 30 min to 
release CoA, which was measured as described above.  
4.9. Biosurfactant Synthesis by Cell-Free Extracts from L-amino Acids, Myristic Acid and CoA 
Cell-free extracts of NHY1 and OKB105 were tested for the ability to synthesize surfactin from  
L-amino acids, myristic acid, and CoA in the presence of H2O2 (substrate for YbdT) and ATP/Mg. 
Cell-free extracts were prepared as described in Ullrich et al. [54] without the ammonium sulfate 
fractionation step. The reaction mixture (0.5 mL) contained 5 mM each of L-aspartate, L-glutamate, 
and L-valine, 0.5 mM L-leucine, 10 mM ATP, 10 mM MgCl2, 13 mM DTE, 6 mM myristic acid,  
6  mM  CoA, 1.32  mm  H2O2, 1.3  mM potassium phosphate, 1 mM EDTA,  and 80 mM Tris  HCl  
(pH 7.8). The reaction was started by the addition of 100 µg  of the cell-free extract. The mixture was 
incubated at 37 ° C for 90 min and then stopped by placing the mixture on ice. The biosurfactant was 
precipitated overnight at room temperature with 40% ammonium sulfate [29]. The precipitate was 
dissolved in 100 µ L water and quantified by HPLC as described above. 
4.10. Determination of the Biosurfactant Structure 
The amino acid and fatty acid compositions, as well as the molecular weight were used to compare 
the structures of the biosurfactants produced by NHY1 and OKB105. Cells were grown in 500-mL 
medium E and biosurfactants were purified as described before [29]. The amino acid composition was 
determined by using cation exchange chromatography at the molecular biology research facility of the 
William K. Warren Research Institute (Oklahoma City, OK, USA) as described before [29]. For fatty 
acid analysis, 200 µg  of the purified biosurfactant was hydrolyzed under vacuum for 16 hours at 90 ° C 
with minimal volume of 6 N HCl in sealed tubes. The hydrolyzed fatty acids were then extracted with 
7 mL of 1:1 v/v ethyl acetate: hexane. The organic phase was concentrated under a stream of N2. The 
concentrated fractions were neutralized with 0.5 mL of 0.4 M phosphate buffer (pH 12) and incubated 
at room temperature for 10 min. The fatty acids in the organic layer were derivatized with BSTFA and 
analyzed by GC/MS. Methanolysis was conducted as described before [29]. To analyze the fatty acids, 
the  mass  spectrometer chromatogram  was  extracted  at  m/z  ratio  of  233  characteristic  of  bis-TMS 
derivatized,  3-hydroxy  fatty  acids,  and  at  m/z  ratio  of  117  characteristic  of  TMS-derivatized,  
non-hydroxylated fatty acids (Figure 2). To analyze the fatty acid methyl esters, the mass spectrometer 
chromatogram was extracted at m/z ratio of 175 characteristic of TMS-derivatized 3-hydroxy fatty  
acid  methyl  ester,  and  at  m/z  ratio  of  74characteristic  of  non-hydroxylated  fatty  acid  methyl  
esters  (Figure 2).  Retention  times  and  mass  spectra  were  compared  to  authentic  standards  of  
methyl-3-hydroxytetradecanoic  acid,  3-hydroxytetradecanoic  acid,  methyltetradecanoic  acid,  and 
tetradecanoic acid (Larodan Fine Chemicals
®, Malamö , Sweden) derivatized as described above.  
The molecular weights of biosurfactants purified from NHY1 and OKB105were determined with 
electrospray ionization mass spectrometry [7,47–49]. The biosurfactants were dissolved in 10 mM Int. J. Mol. Sci. 2011, 12                       
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ammonium  hydroxide  to  a  final  concentration  of  0.05  µ g/µL .  The  solvent  system  used  was  
75% methanol: 25% water. Samples were run in the negative mode. 
5. Conclusions 
An in-frame mutation of ybdT was obtained and phenotypic characterization of the mutant strain 
(NHY1)  showed  that  YbdT  catalyzes  the  formation  of  3-hydroxy  LCFA  needed  for  lipopeptide 
biosurfactant synthesis in B. subtilis. NHY1 produced predominantly non-hydroxylated lipopeptide 
biosurfactants  with  diminished  activity.  Site-directed  mutagenesis  of  the  enzyme  responsible  for  
3-hydroxylation of LCFA could provide a new avenue to design biosurfactants tailored for specific 
functions by altering the 3-hydroxy fatty acid composition of the biosurfactant. 
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